Intellistent: a minimally invasive, adjustable pulmonary flow restrictor system for congenital and acquired heart disease
Active Project Grant Awarded Last action
- Award ID
- R44HL182590
- Recipient
-
Heartpoint Global Inc. UEI PA71QLU96QM6
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,011,780
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 59% complete
- Place of performance
- Coral Gables, FL 33134, USA
Award details come from USAspending.gov.
Description
- Abstract
- Heartpoint global's intellistent is the first minimally invasive, adjustable pulmonary flow restrictor developed for pediatric and congenital heart disease (CHD) patients. Treatments to modify pulmonary flow in the pediatric and CHD populations are currently limited to open-chest pulmonary artery banding (PAB) and expensive medication regimens. Both of these treatments have severe limitations, including significant risks of morbidity and mortality, and have high rates of failure. There is a critical unmet need to develop novel treatments that are both more effective and less risky than current approaches. Previous attempts to adapt devices designed for adult cardiovascular treatments have been unsuccessful, largely due to the unique characteristics of pediatric and CHD patients. Intellistent is currently developed in a size range suitable for patients 12 years and up, with successful pre-clinical testing completed that showed no signs of thrombosis in chronic (9.5 month) studies. RE- engineering the intellistent in a size range suitable for neonates and infants would represent the first minimally- invasive treatment specifically developed for children. This proposal aims to prepare intellistent for first-in-human testing for sizes in patients from birth. Our specific aims are: (1) downsize the intellistent to be suitable for patients from birth, including preclinical testing; (2) complete biocompatibility testing as required for regulatory submission; and, (3) optimize manufacturing processes for clinical and commercial production. Successful completion of this proposal would bring to market a novel treatment for pulmonary flow modification and represent a transformative step in the treatment of pediatric patients with congenital and acquired heart disease.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1,240,696 | |
| Original award | $1,771,084 |
Quick answers
Who received award R44HL182590?
R44HL182590 was awarded to Heartpoint Global Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 1, 2025.
How much is award R44HL182590 worth?
$3,011,780 has been obligated on R44HL182590.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award